Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)”

50 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 50 results

Testing effectiveness (Phase 2)Study completedNCT00806598
What this trial is testing

Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic SyndromeAplastic Anemia
M.D. Anderson Cancer Center 53
Large-scale testing (Phase 3)Ended earlyNCT00804050
What this trial is testing

Multicentric Study Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-cis-retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts

Who this might be right for
Myelodysplastic Syndromes
Fondazione Italiana Sindromi Mielodisplastiche-ETS 184
Large-scale testing (Phase 3)Study completedNCT01362140
What this trial is testing

Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
MDS
Amgen 147
Testing effectiveness (Phase 2)Ended earlyNCT01542684
What this trial is testing

Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 8
Testing effectiveness (Phase 2)Study completedNCT00614523
What this trial is testing

Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
MDSMyelodysplastic SyndromesThrombocytopenia
Amgen 250
Testing effectiveness (Phase 2)Study completedNCT02269280
What this trial is testing

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 185
Testing effectiveness (Phase 2)Study completedNCT01749514
What this trial is testing

Study of Luspatercept for the Treatment of Anemia in Patients With Myelodysplastic Syndrome (MDS) (MK-6143-001)

Who this might be right for
Anemia
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA 116
Testing effectiveness (Phase 2)Study completedNCT02268383
What this trial is testing

Extension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS) (A536-05/MK-6143-003)

Who this might be right for
Myelodysplastic Syndromes
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA 75
Testing effectiveness (Phase 2)Study completedNCT02363491
What this trial is testing

A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome
Opsona Therapeutics Ltd. 96
Not applicableStudy completedNCT02279654
What this trial is testing

Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q)

Who this might be right for
Myelodysplastic Syndrome
Celgene 389
Large-scale testing (Phase 3)Active Not RecruitingNCT00843882
What this trial is testing

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Who this might be right for
AnemiaChronic Myelomonocytic LeukemiaDe Novo Myelodysplastic Syndrome+1 more
National Cancer Institute (NCI) 247
Testing effectiveness (Phase 2)Study completedNCT01081431
What this trial is testing

Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q

Who this might be right for
Myelodysplastic Syndromes
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH 91
Not applicableStudy completedNCT04036448
What this trial is testing

A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea

Who this might be right for
Myelodysplastic SyndromesLymphoma, Mantle-CellLymphoma, Follicular
Celgene 28
Early research (Phase 1)WithdrawnNCT02075034
What this trial is testing

Three Dosing Schedules of Oral Rigosertib in MDS Patients

Who this might be right for
Myelodysplastic Syndrome
Traws Pharma, Inc.
Early research (Phase 1)Ended earlyNCT00458159
What this trial is testing

A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndrome
Celgene 34
Testing effectiveness (Phase 2)UnknownNCT00513578
What this trial is testing

Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndromes
The Vaccine Company 30
Large-scale testing (Phase 3)Ended earlyNCT00695396
What this trial is testing

A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion

Who this might be right for
Myelodysplastic SyndromesAnemia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 25
Testing effectiveness (Phase 2)Ended earlyNCT00495547
What this trial is testing

SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome
PETHEMA Foundation 16
Testing effectiveness (Phase 2)Ended earlyNCT02599649
What this trial is testing

Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 10
Testing effectiveness (Phase 2)Study completedNCT00619099
What this trial is testing

Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic Syndrome
Eisai Inc. 67
Next Page